| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CA1 |
| Uniprot No | P00915 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-261aa |
| 氨基酸序列 | ASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF |
| 预测分子量 | 30.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CA1重组蛋白的模拟参考文献示例，供参考：
---
1. **文献名称**: *Expression and Purification of Recombinant Human Carbonic Anhydrase I in E. coli*
**作者**: Smith A, et al.
**摘要**: 研究报道了在大肠杆菌中高效表达人源CA1(碳酸酐酶I)重组蛋白的优化方法，通过亲和层析纯化获得高活性蛋白，并验证其催化CO₂水合反应的酶动力学特性。
2. **文献名称**: *Structural Insights into CA1 by X-ray Crystallography*
**作者**: Lee S, et al.
**摘要**: 利用重组CA1蛋白进行X射线晶体学分析，解析其三维结构，揭示了活性位点关键氨基酸残基在催化中的作用，为设计靶向抑制剂提供结构基础。
3. **文献名称**: *CA1 as a Serum Biomarker in Cancer: Recombinant Protein-based Antibody Development*
**作者**: Zhang Y, et al.
**摘要**: 通过重组CA1蛋白制备单克隆抗体，验证其在结直肠癌患者血清中的高表达，提出CA1作为潜在诊断标志物的临床应用价值。
4. **文献名称**: *Functional Characterization of CA1 Mutants in Metabolic Disorders*
**作者**: Johnson R, et al.
**摘要**: 构建CA1点突变重组蛋白，分析其酶活缺陷与代谢性酸中毒的关联，探讨CA1基因突变导致疾病的分子机制。
---
**注**：以上文献为示例，如需真实文献，请提供更具体的研究方向或通过学术数据库(如PubMed)检索关键词“recombinant CA1 protein”或“Carbonic Anhydrase I recombinant”。
CA1 recombinant protein, derived from the human carbonic anhydrase 1 (CA1) gene, is a genetically engineered protein widely used in biochemical and biomedical research. Carbonic anhydrases (CAs) are a family of zinc-containing metalloenzymes that catalyze the reversible hydration of carbon dioxide (CO₂) to bicarbonate (HCO₃⁻) and protons (H⁺), playing critical roles in pH regulation, CO₂ transport, and electrolyte balance. CA1. primarily expressed in erythrocytes and certain epithelial tissues, is involved in physiological processes such as respiration, acid-base homeostasis, and bone resorption. Dysregulation of CA1 has been linked to diseases like cancer, glaucoma, and metabolic acidosis, making it a target for therapeutic and diagnostic studies.
Recombinant CA1 is produced using expression systems such as *E. coli*, yeast, or mammalian cells, enabling large-scale production with high purity and consistency. The protein is typically purified via affinity chromatography, retaining its enzymatic activity and structural integrity. Its recombinant form allows researchers to study CA1's kinetic properties, inhibition mechanisms, and interactions with drugs like acetazolamide, a carbonic anhydrase inhibitor used clinically.
In drug discovery, CA1 recombinant protein serves as a tool for screening inhibitors targeting CA isoforms, aiding in the development of treatments for CA-related disorders. It is also utilized in diagnostic assays to detect CA1 autoantibodies in autoimmune conditions. Additionally, structural studies using recombinant CA1 have provided insights into enzyme catalysis and zinc-binding motifs, advancing our understanding of metalloprotein function. By bypassing challenges associated with isolating CA1 from natural sources, recombinant technology ensures scalability and reproducibility, supporting both academic and industrial applications in enzymology, pharmacology, and molecular medicine.
×
